Author

Peter Bossuyt 1

1 Imelda General Hospital, Bonheiden, Belgium

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Geert R. D'Haens, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, Rachel Duan, Kristina Kligys, Marla C. Dubinsky

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

ACCELERATED STEP-UP APPROACH AND LONG-TERM DISEASE OUTCOMES IN PAEDIATRIC PATIENTS WITH CROHN?S DISEASE

Lucas Wauters, Françoise Smets, Ilse Hoffman, Elisabeth De Greef, Patrick Bontems, Philippe Alliet, Wim Arts, Bruno Hauser, Stephanie Van Biervliet, Els Van de Vijver, Isabelle Paquot, Harald Peeters, Peter Bossuyt, Jean François Rahier, Tom Moreels, Olivier Dewit, Denis Franchimont, Vinciane Muls, Fernand Fontaine, Edou

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

CHARACTERISTICS OF CHILDREN WITH CROHN?S DISEASE FAILING SUSTAINED REMISSION DESPITE ANTI-TNF EXPOSURE

Lucas Wauters, Françoise Smets, Ilse Hoffman, Elisabeth De Greef, Patrick Bontems, Philippe Alliet, Wim Arts, Bruno Hauser, Stephanie Van Biervliet, Els Van de Vijver, Isabelle Paquot, Harald Peeters, Peter Bossuyt, Jean François Rahier, Tom Moreels, Olivier Dewit, Denis Franchimont, Vinciane Muls, Fernand Fontaine, Edou

DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY

Peter Bossuyt, Geert R. D'Haens, Remo Panaccione, William Sandborn, Walter Reinisch, Simon Travis, Stefan Schreiber, Alessandro Armuzzi, Silvio Danese, Sofie Berg, Joel Petersson, Jen-Fue Maa, Ezequiel Neimark, Jean-Frederic Colombel

DE-ESCALATING THERAPY IN PATIENTS WITH CROHN’S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY

Peter Bossuyt

Disease monitoring with biomarkers and endoscopy: How to best combine them?

Peter Bossuyt

Disease monitoring with biomarkers and endoscopy: How to best combine them?

Peter Bossuyt

EARLY FIBROSTENOSIS IN CROHN’S DISEASE IS ASSOCIATED WITH MULTIPLE SUSCEPTIBILITY LOCI ON IMMUNOCHIP ANALYSIS

Tom Holvoet, Peter Bossuyt, Isabelle Cleynen, Isabelle De Kock, Pieter Hindryckx, Severine Vermeire, Debby Laukens, Martine De Vos

Item 1 - 10 / 55
1
2 3 4 5 6